MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-20-1767

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.

Chen Runzhe, Lee Won-Chul, Fujimoto Junya, Li Jun, Hu Xin, Mehran Reza, Rice David, Swisher Stephen G, Sepesi Boris, Tran Hai T, Chow Chi-Wan, Little Latasha D, Gumbs Curtis, Haymaker Cara, Heymach John V, Wistuba Ignacio I, Lee J Jack, Futreal P Andrew, Zhang Jianhua, Reuben Alexandre, Tsao Anne S, Zhang Jianjun

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Malignant pleural mesothelioma (MPM) is considered an orphan disease with few treatment options. Despite multimodality therapy, the majority of MPMs recur and eventually become refractory to any systemic treatment. One potential mechanism underlying therapeutic resistance may be intratumor heterogeneity (ITH), making MPM challenging to eradicate. However, the ITH architecture of MPM and its clinical impact have not been well studied.

EXPERIMENTAL

DESIGN

We delineated the immunogenomic ITH by multiregion whole-exome sequencing and T-cell receptor (TCR) sequencing of 69 longitudinal MPM specimens from nine patients with resectable MPM, who were treated with dasatinib.

RESULTS

The median total mutation burden before dasatinib treatment was 0.65/Mb, similar with that of post-dasatinib treatment (0.62/Mb). The median proportion of mutations shared by any given pair of two tumor regions within the same tumors was 80% prior to and 83% post-dasatinib treatment indicating a relatively homogenous genomic landscape. T-cell clonality, a parameter indicating T-cell expansion and reactivity, was significantly increased in tumors after dasatinib treatment. Furthermore, on average, 82% of T-cell clones were restricted to individual tumor regions, with merely 6% of T-cell clones shared by all regions from the same tumors indicating profound TCR heterogeneity. Interestingly, patients with higher T-cell clonality and higher portion of T cells present across all tumor regions in post-dasatinib-treated tumors had significantly longer survival.

CONCLUSIONS

Despite the homogeneous genomic landscape, the TCR repertoire is extremely heterogeneous in MPM. Dasatinib may potentially induce T-cell response leading to improved survival.

Для цитирования: Chen Runzhe, Lee Won-Chul, Fujimoto Junya, Li Jun, Hu Xin, Mehran Reza, Rice David, Swisher Stephen G, Sepesi Boris, Tran Hai T, Chow Chi-Wan, Little Latasha D, Gumbs Curtis, Haymaker Cara, Heymach John V, Wistuba Ignacio I, Lee J Jack, Futreal P Andrew, Zhang Jianhua, Reuben Alexandre, Tsao Anne S, Zhang Jianjun. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. DOI: 10.1158/1078-0432.ccr-20-1767.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.